Elevance Health's stock saw significant volatility this week, initially dropping 5% due to a disappointing 2026 revenue forecast, but rebounded by 6% after reporting strong fourth-quarter earnings with $3.33 per share and $50.09 billion in revenue. Despite the bounce, the company's stock has lost 7.9% year-to-date, and concerns about flat Medicare rates for 2027 pushed shares down an additional 14.33%. To reassure investors, Elevance announced a $2.3 billion allocation for share repurchases.
“Elevance Health · stock fell · 5% · before the bell on Wednesday following a 2026 forecast for profit falling below Wall Street estimates”
“Elevance Health · rallied · 6% · after fourth-quarter earnings per share and premium revenue beat Street estimates”
“Elevance Health · closed · up more than +5%”
“Elevance Health · said · it will allocate to share repurchases · $2.3 billion”
“Elevance Health · shares fell · premarket · ~6%”
“Elevance Health · estimated total operating revenue · 2026 · low single-digit decline”
“Elevance Health · generating adjusted diluted earnings per share · at least · $25.50”
“Elevance Health · reported revenues of · $50.09 billion · up 12% year on year”
“Elevance Health · beat analysts’ expectations by · 1.2%”
“Elevance Health · lost customers and ended up with a total of · 45.37 million · 252,000”
“Elevance Health · said it will allocate · to share repurchases · $2.3 billion”
“Elevance Health · is up · 5% · +5%”